LONDON (ShareCast) - (Sharecast News) - Trellus Health announced a 12-month contract with one of the world's largest clinical research organisations on Wednesday, to support recruitment and enrolment for a mid-stage immunology and inflammation trial, marking a key milestone in its expansion into the clinical trials sector.
The AIM-traded company, which delivers digital resilience and behavioural science solutions for chronic condition management, said the new agreement includes an upfront payment, monthly management fees and milestone-linked payments.

It said the contract's performance would be measured against three key indicators - the number of potential participants joining the 'Trellus TrialSet' programme, the increase in qualified candidates referred for screening, and the reduction in screen-failure rates.

As part of the initiative, Trellus launched Trellus TrialSet, a new programme designed to improve trial recruitment and retention by identifying participants with low resilience and providing tailored education, engagement, and support to enhance their readiness to take part.

The firm said the approach aimed to improve recruitment efficiency, reduce dropouts and generate cost savings for research partners.

"Clinical trials continue to face challenges in recruitment, retention and study completion," said chief executive Dr Marla Dubinsky.

"We are proud to launch Trellus TrialSet to directly address these issues by proactively assessing and preparing participants, ensuring only those who are ready will enter the trial.

"This resilience-based approach is designed to significantly reduce screen failures and dropouts while delivering meaningful cost savings for our partners."

Dubinsky added that while the new contract would not immediately extend Trellus's cash runway beyond early December, it demonstrated the company's ability to win work from major global CROs and build commercial traction.

Trellus also announced it gad been granted preferred vendor status by a second leading global CRO to support recruitment for another clinical programme.

While the designation was not revenue-generating, it provided access to the CRO's client base and streamlines procurement and contracting processes, the company said.

At 1259 BST, shares in Trellus Healtgh were up 10.77% at 0.72p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE